Compare MCO & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCO | GSK |
|---|---|---|
| Founded | 1900 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.9B | 95.3B |
| IPO Year | 2000 | N/A |
| Metric | MCO | GSK |
|---|---|---|
| Price | $484.89 | $48.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 1 |
| Target Price | ★ $541.47 | N/A |
| AVG Volume (30 Days) | 755.6K | ★ 4.2M |
| Earning Date | 10-22-2025 | 10-29-2025 |
| Dividend Yield | 0.77% | ★ 3.40% |
| EPS Growth | 13.55 | ★ 118.57 |
| EPS | ★ 12.42 | 1.79 |
| Revenue | $7,501,000,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $9.45 | $6.56 |
| Revenue Next Year | $7.57 | $5.13 |
| P/E Ratio | $39.19 | ★ $27.33 |
| Revenue Growth | ★ 8.77 | 2.73 |
| 52 Week Low | $378.71 | $31.72 |
| 52 Week High | $531.93 | $49.31 |
| Indicator | MCO | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 50.69 | 60.04 |
| Support Level | $473.46 | $47.20 |
| Resistance Level | $498.00 | $49.31 |
| Average True Range (ATR) | 7.76 | 0.61 |
| MACD | -0.14 | -0.04 |
| Stochastic Oscillator | 51.56 | 81.02 |
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed-income securities. The ratings segment, Moody's Investors Service, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's profit and often (depending on bond issuance levels) a majority of the firm's revenue. The other segment, Moody's Analytics, consists of decision solutions, research and insights, and data and information.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.